Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Buhai Wang"'
Autor:
Zhihao Lu, Li Kong, Buhai Wang, Junye Wang, Lianke Liu, Yongqian Shu, Lei Yang, Guogui Sun, Guochun Cao, Yinghua Ji, Tongjian Cui, Hu Liu, Wensheng Qiu, Na Li, Gaofeng Li, Hui Luo, Xinfang Hou, Yanqiao Zhang, Wenbin Yue, Liying Xue, Zheng Liu, Yueyin Pan, Shegan Gao, Xiuwen Wang, Zhanyu Pan, Shuqun Zhang, Gen Lin, Yanru Xie, Kangsheng Gu, Tiejun Ren, Weidong Li, Tao Li, Shoufeng Wang, Wei He, Yun Fan, Jun Liang, Bing Xia, Li Zhao, Shuxuan Wang, Lin Shen
Publikováno v:
EClinicalMedicine, Vol 72, Iss , Pp 102623- (2024)
Summary: Background: In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here,
Externí odkaz:
https://doaj.org/article/3439ece3dd7b46968792b2d1c86fbbe8
Autor:
Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100621- (2024)
Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improveme
Externí odkaz:
https://doaj.org/article/a94bd03454c54595bceebab2019eeee9
Autor:
Yichun Zeng, Liying Zhang, Yichen Liang, Xian Zhang, Lei Li, Maoqi Wang, Jingliang Guo, Qiuxian Li, Jin Cao, Juan J. Gu, Buhai Wang
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 13928-13941 (2023)
Abstract Background Currently, immune checkpoint blockers (ICB) and radiotherapy (RT) combination therapy is broadly applied in non‐small cell lung cancer (NSCLC) patients. However, meta‐analysis about safety and efficacy of RT + ICB versus ICB h
Externí odkaz:
https://doaj.org/article/302bb34d569445298a091f62ee3d33bd
Autor:
Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang
Publikováno v:
Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)
Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation
Externí odkaz:
https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce
Autor:
Buhai Wang, Caiyue Chen, Shiyu Jiang, Yuxiang Huang, Yichun Zeng, Lei Li, Maoqi Wang, Jingliang Guo, Qiuxian Li, Jin Cao, Long Shen, Juan J Gu, Yichen Liang
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 17 (2023)
Background: Programmed cell death-1 (PD-1) blockade has been shown to confer clinical benefit in cancer patients. Here, we assessed the level of serum interleukin 14α (IL14α) in patients receiving anti-PD-1 treatment. Methods: This prospective stud
Externí odkaz:
https://doaj.org/article/3f673ffd49524574873850df32eeb489
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Purpose: The purpose of this study was to investigate the effect of MYC and TP53 comutations on the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced EGFR-positive nonsmall-cell lung cancer (NSCLC). Patient
Externí odkaz:
https://doaj.org/article/94f070f1e8c44fb9b1e6ae58ba3c4f95
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Background: Long non-coding RNA (LncRNA) is a prognostic factor for malignancies, and N7-Methylguanosine (m7G) is crucial in the occurrence and progression of tumors. However, it has not been documented how well m7G-related LncRNAs predict the develo
Externí odkaz:
https://doaj.org/article/5800640698394aadab72993e5cd7cc3e
Autor:
Lei Li, Buhai Wang
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Lung adenocarcinoma is the most common histological subtype of lung cancer which causes the largest number of deaths worldwide. Exploring reliable prognostic biomarkers based on biological behaviors and molecular mechanisms is essential for predictin
Externí odkaz:
https://doaj.org/article/13daee0b5c8e4c8aaadf71c8a515ad08
Autor:
Buhai Wang, Jiangquan Yu, Yichun Zeng, Xian Zhang, Chongxu Han, Qili Lu, Xiaolin Wang, Yichen Liang, Juan J. Gu, Yusheng Shu
Publikováno v:
Clinical and Translational Discovery, Vol 2, Iss 1, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/77466ebe679d446a81d87b2c4a7ea625
Autor:
Buhai Wang, Yaqin Fan, Liying Zhang, Liqin Liu, Yutong Ma, Xiaosong Ma, Yuxiang Huang, Yinxia Wu, Yichen Liang, Yang Xu, Xue Wu
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 16 (2022)
Introduction: Pembrolizumab is widely used in advanced non-small-cell lung cancer (NSCLC) patients with positive programmed death-ligand 1 (PD-L1). However, efficacy evaluation along treatment by serial monitoring of circulating tumor DNA (ctDNA) usi
Externí odkaz:
https://doaj.org/article/009c99a26287480ab04c39dcd8ad88f5